Annexin A3 is a potential angiogenic mediator

Area of Science:

• Biochemistry
• Molecular Biology
• Cell Biology

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for development and implicated in diseases like cancer.
• Dysregulation of angiogenesis contributes to pathological conditions, including tumor growth and rheumatoid arthritis.
• While many angiogenic factors are known, the complexity of the process necessitates identifying novel protein regulators.

Purpose of the Study:

• To investigate the role of annexin A3 (ANXA3) in angiogenesis.
• To determine the mechanism by which ANXA3 influences endothelial cell behavior and angiogenic factor production.

Main Methods:

• Transfection of cells with ANXA3 expression plasmid.
• Assessment of endothelial cell migration and tube formation.
• Measurement of vascular endothelial growth factor (VEGF) levels in conditioned media.
• Reporter assays to evaluate hypoxia-inducible factor-1 (HIF-1) transactivation activity.

Main Results:

• Annexin A3 (ANXA3) significantly induced migration and tube formation in human umbilical vein endothelial cells.
• Cells expressing ANXA3 showed elevated levels of vascular endothelial growth factor (VEGF).
• ANXA3 was found to enhance the transactivation activity of hypoxia-inducible factor-1 (HIF-1).

Conclusions:

• Annexin A3 (ANXA3) acts as a novel angiogenic factor.
• ANXA3 stimulates VEGF production through the HIF-1 signaling pathway.
• These findings suggest ANXA3 as a potential therapeutic target for angiogenesis-related disorders.